Sparlon

Treatment for ADHD in Children and Adolescents

Cephalon Receives Approvable Letter for Sparlon for the Treatment of ADHD in Children and Adolescents

Sparlon is a new formulation and proprietary dosage strength of modafinil, the active ingredient in Provigil (modafinil) Tablets [C-IV], which is approved for the treatment of adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder. Provigil is not approved to treat ADHD and is available only in 100 mg and 200 mg strengths. If approved, Sparlon is expected to be available in early 2006.

Source: Cephalon, Inc.

Posted: October 2005

Related Articles

Sparlon (modafinil) FDA Approval History

View comments

Hide
(web3)